Literature DB >> 23263403

Pyoderma gangrenosum occurring at the peri-ileal pouch-anal anastomosis in a patient with ulcerative colitis: report of a case.

Koji Tanaka1, Toshimitsu Araki, Yoshiki Okita, Hiroyuki Fujikawa, Mikio Kawamura, Keiichi Uchida, Yasuhiko Mohri, Masato Kusunoki.   

Abstract

Pyoderma gangrenosum (PG) is an idiopathic, inflammatory, ulcerative skin disorder; the etiology and pathogenesis of which are still poorly understood. It is one of the most important extraintestinal manifestations that can appear in the course of ulcerative colitis (UC). Although skin ulcers with destructive and necrotizing components are more commonly observed on the lower extremities and trunk, PG at stomal sites (peri-stomal PG) has been increasingly reported in patients with inflammatory bowel diseases (IBDs), including UC. Although PG at various surgical sites has been reported as an unusual presentation of PG, postoperative PG developing at the ileal pouch-anal anastomosis (IPAA) has not been reported previously. We herein report the first published case of a patient with UC who developed peri-anastomotic PG after IPAA during the postoperative tapering of systemic corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23263403     DOI: 10.1007/s00595-012-0463-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Adalimumab for pyoderma gangrenosum associated with inflammatory bowel disease.

Authors:  Irune Cariñanos; Manuel Barreiro-De Acosta; Eugeni Domènech
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

Review 2.  Pyoderma gangrenosum: uncommon presentations.

Authors:  Sharareh Ahmadi; Frank C Powell
Journal:  Clin Dermatol       Date:  2005 Nov-Dec       Impact factor: 3.541

3.  The use of etanercept in the treatment of peristomal pyoderma gangrenosum.

Authors:  F S Kim; A G Pandya
Journal:  Clin Exp Dermatol       Date:  2012-06       Impact factor: 3.470

4.  Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.

Authors:  T N Brooklyn; M G S Dunnill; A Shetty; J J Bowden; J D L Williams; C E M Griffiths; A Forbes; R Greenwood; C S Probert
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

5.  Systemic pyoderma gangrenosum responding to infliximab and adalimumab.

Authors:  V G Hubbard; A C Friedmann; P Goldsmith
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

6.  Neutrophil dysfunction in steroid-overdosed patients with ulcerative colitis: potential relevance of macrophage migration inhibitory factor to increased postoperative morbidity.

Authors:  Yoshiki Okita; Chikao Miki; Shigeyuki Yoshiyama; Kohei Otake; Toshimitsu Araki; Keiichi Uchida; Masato Kusunoki
Journal:  Surg Today       Date:  2011-10-04       Impact factor: 2.549

Review 7.  Pyoderma gangrenosum: a review and update on new therapies.

Authors:  Jeremiah Miller; Brad A Yentzer; Adele Clark; Joseph L Jorizzo; Steven R Feldman
Journal:  J Am Acad Dermatol       Date:  2010-04       Impact factor: 11.527

8.  Topical tacrolimus for parastomal pyoderma gangrenosum: a report of two cases.

Authors:  Maria Altieri; Khashayar Vaziri; Bruce A Orkin
Journal:  Ostomy Wound Manage       Date:  2010-09       Impact factor: 2.629

Review 9.  Pyoderma gangrenosum: an updated review.

Authors:  E Ruocco; S Sangiuliano; A G Gravina; A Miranda; G Nicoletti
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-03-11       Impact factor: 6.166

10.  Mucocutaneous manifestations in inflammatory bowel disease.

Authors:  Ilhami Yüksel; Omer Başar; Hilmi Ataseven; Ibrahim Ertuğrul; Mehmet Arhan; Mehmet Ibiş; Ulkü Dağli; Bilge Tunç Demirel; Aysel Ulker; Sema Seçilmiş; Nurgül Saşmaz
Journal:  Inflamm Bowel Dis       Date:  2009-04       Impact factor: 5.325

View more
  1 in total

1.  Extensive phlegmon and pyoderma gangrenosum: diagnostic difficulties.

Authors:  Dominika Wcisło-Dziadecka; Beata Bergler-Czop; Ligia Brzezińska-Wcisło; Hubert Arasiewicz
Journal:  Postepy Dermatol Alergol       Date:  2015-02-04       Impact factor: 1.837

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.